Acute myeloid leukaemia (AML) - management overview
AML · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A rapidly progressive clonal expansion of myeloid blasts causing marrow failure. Management requires urgent diagnosis, molecular/cytogenetic risk stratification, and either intensive induction chemotherapy or lower-intensity regimens with targeted agents.
Red flags
- Coagulopathy suggesting acute promyelocytic leukaemia
- Hyperleukocytosis with leukostasis (hypoxia, confusion)
- Tumour lysis syndrome
- Neutropenic sepsis
- Rapidly rising blast count
Assessment
Differential diagnosis
- Acute lymphoblastic leukaemia
- Blast-phase CML
- Myelodysplastic syndrome
- Aplastic anaemia
- Leukaemoid reaction
- Acute promyelocytic leukaemia
Investigations
- FBC, film and blast count; coagulation screen (exclude APL/DIC)
- Bone marrow aspirate/trephine with immunophenotyping
- Cytogenetics and molecular panel (FLT3, NPM1, IDH1/2, CEBPA, TP53)
- Tumour lysis labs (urate, potassium, phosphate, calcium, renal function)
- LDH, fibrinogen, LFTs
- HLA typing and infection screen for transplant planning
Management
- Recognise urgently - cytopenias with circulating blasts need same-day haematology
- Exclude acute promyelocytic leukaemia immediately (coagulopathy is life-threatening and treatment differs)
- Stabilise: transfusion support, treat sepsis, start tumour lysis prophylaxis
- Confirm diagnosis and perform full genetic risk stratification
- Decide intensity by fitness, age and genetics
- For fit patients give intensive induction (anthracycline plus cytarabine, '7+3')
- For unfit/older patients use venetoclax plus a hypomethylating agent
- Add targeted agents where indicated (FLT3 inhibitors, IDH inhibitors, gemtuzumab for CD33+)
- Assess remission by marrow and measurable residual disease; consolidate accordingly
- Refer high-risk/relapsed disease for allogeneic stem cell transplant and provide intensive supportive care
Drugs & doses
Cytarabine 100-200 mg/m2/day IV continuous for 7 days plus daunorubicin 60 mg/m2 IV days 1-3 (intensive '7+3')
Venetoclax (ramp-up to 400 mg PO daily) plus azacitidine 75 mg/m2 SC/IV days 1-7 (lower intensity)
Midostaurin/quizartinib for FLT3-mutated; allopurinol or rasburicase for tumour lysis prophylaxis
Broad-spectrum antimicrobials for neutropenic sepsis
Disposition
Immediate admission to a haematology/oncology centre; intensive supportive care; transplant referral for high-risk disease.
Complications & pitfalls
- Neutropenic sepsis
- Tumour lysis syndrome
- DIC (especially APL)
- Leukostasis
- Treatment-related marrow aplasia and organ toxicity
- Relapse
Exam pearls
- Always exclude APL first - its coagulopathy kills early and ATRA is urgent
- Molecular genetics now drive both prognosis and targeted therapy choice
- Venetoclax-azacitidine has transformed outcomes for older unfit patients
- Measurable residual disease guides transplant decisions
- Start tumour lysis prophylaxis before cytoreduction
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.